BLAInjectionInjectablePriority Review
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LUCENTIS (ranibizumab) by Roche is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2006.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUCENTIS (ranibizumab) is a monoclonal antibody fragment that inhibits vascular endothelial growth factor (VEGF), approved in 2006 for wet age-related macular degeneration and other retinal conditions. Administered as an intravitreal injection, it reduces abnormal blood vessel growth and fluid leakage in the eye. The drug represents a foundational anti-VEGF therapy in ophthalmology.
$0.004BPart D
LOE ApproachingDeclining
As LOE approaches, LUCENTIS teams face headcount pressure and resource reallocation toward newer formulations and biosimilar defense strategies.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Started Nov 2025
250 enrolled
Neovascular Age-related Macular Degeneration
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
Started Oct 2024
406 enrolled
Diabetic Macular Edema (DME)
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Started Jun 2024
68 enrolled
Neovascular Age-related Macular DegenerationnAMD
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Started Dec 2023
0Neovascular Age-Related Macular Degeneration
A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China
Started Jan 2023
62 enrolled
Retinopathy of Prematurity
Worked on LUCENTIS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.